The role of immune checkpoint inhibition in the treatment of ovarian cancer
about
Ovarian cancer stem cells: still an elusive entity?Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical reviewExosomal DNMT1 mediates cisplatin resistance in ovarian cancer.Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments.The latest animal models of ovarian cancer for novel drug discovery.Ovarian cancer: how can resistance to chemotherapy be tackled?Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.Advances in ovarian cancer therapy.Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.GADD45β loss ablates innate immunosuppression in cancer.Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer.Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.The role of Cediranib in ovarian cancer.NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.Major clinical research advances in gynecologic cancer in 2017.Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
P2860
Q37713683-C15E7AB1-D0E5-4DD9-AC31-109A5A26D715Q37724905-3BEF0BD8-581D-48DA-B348-7E8784CC9E10Q38632732-F2759A37-A385-4F35-A9D4-764BA5F1F471Q42099922-BC445767-CC3B-445A-8123-EE783511D87EQ47553013-6CE9F125-0F16-498B-97C9-8A9955FFA239Q47813897-48D96C2B-CA4C-4C47-9746-0D26492F97F2Q47862144-1391AE34-F303-46CF-B692-4183C85F1D5BQ48104995-1D4B1AF4-1FDC-4CA7-8F45-A7CD2DE798C6Q48124146-5388A12C-10E7-4093-A0BB-0A652D352598Q49568351-55A6EBF7-67C4-4084-87DF-E7437676133DQ49885235-0622FF60-AEAC-4DF0-8C21-5B14B95319F1Q49913387-4056182F-693B-470C-AD55-667AB87EFE6FQ49966031-2E3481E8-A266-47FE-A0D9-AB0BA5718CA8Q51065844-F1FB6F53-4F59-469E-8DF0-E72DCE769AE8Q51183547-6F0CC9FF-237F-47D6-94B4-E56D111BE3BDQ52590080-B7CB30B3-1419-455C-B26D-22843A0BD2ECQ54952356-EAC72CA9-31B3-4BAD-944E-72EC6A72077DQ54993659-463B9357-253F-4C01-BF75-9729558BCC5EQ55209571-A1B1E621-61CC-4712-BE18-66C18011F9C8Q55282202-5319B14F-3DA2-4A4F-83D8-44F799447EE9
P2860
The role of immune checkpoint inhibition in the treatment of ovarian cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@ast
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@en
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@nl
type
label
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@ast
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@en
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@nl
prefLabel
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@ast
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@en
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@nl
P2093
P2860
P1476
The role of immune checkpoint inhibition in the treatment of ovarian cancer
@en
P2093
Angeles A. Secord
Bradley Monk
Stéphanie L. Gaillard
P2860
P2888
P356
10.1186/S40661-016-0033-6
P407
P577
2016-11-24T00:00:00Z
P6179
1005055325